Oxytetracycline
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Oxytetracycline: From Bacterial Infections to Chronic Rhinosinusitis
One-Sentence Summary
Oxytetracycline is a tetracycline-class antibiotic historically used to treat broad-spectrum bacterial infections; it currently holds no UK marketing authorisation. The TxGNN model predicts it may be effective for Chronic Rhinosinusitis, but this direction is currently supported by 0 clinical trials and 0 publications — the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (broad-spectrum antibacterial; no formal UK licence currently on file) |
| Predicted New Indication | Chronic Rhinosinusitis |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for oxytetracycline in this evidence pack. Based on known pharmacology, oxytetracycline belongs to the tetracycline class of antibiotics, whose antibacterial efficacy in respiratory and other bacterial infections is well established through decades of clinical use, even though it currently lacks a UK marketing authorisation.
The rationale linking oxytetracycline to chronic rhinosinusitis is indirect. Chronic rhinosinusitis frequently involves bacterial colonisation and mucosal inflammation, and a related tetracycline, doxycycline, has published support for an anti-inflammatory effect (matrix metalloproteinase inhibition) independent of its antibacterial action. By class analogy, a similar mechanism is biologically plausible for oxytetracycline. However, this is an extrapolation from a related molecule rather than direct evidence — no clinical trials or literature specific to oxytetracycline in chronic rhinosinusitis currently exist.
Given the complete absence of direct supporting data, this candidate should be regarded as a research hypothesis generated by the knowledge graph rather than a clinically actionable signal at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Detailed warnings, contraindications and drug interaction data for oxytetracycline were not available in this evidence pack (flagged as a Blocking data gap for TFDA/MHRA label information). This must be resolved before any safety review can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for chronic rhinosinusitis is supported only by a TxGNN model score (L5 evidence) and an indirect class-analogy argument via doxycycline; there are no direct clinical trials or publications for oxytetracycline in this indication, and no UK marketing authorisation currently exists for the drug.
To proceed, the following is needed:
- Mechanism of action (MOA) data for oxytetracycline (currently a data gap, High severity)
- MHRA/SmPC warnings, contraindications and DDI data (currently a data gap, Blocking severity) — required before any safety evaluation
- Direct preclinical or clinical evidence specific to oxytetracycline in chronic rhinosinusitis, rather than extrapolation from doxycycline
- Consideration of whether pathway resources are better directed toward other candidates in this same evidence pack with materially stronger evidence — notably otitis externa (rank 10), which has an L2 evidence level, one relevant clinical trial, and 21 supporting publications including several RCTs, with a “Proceed with Guardrails” recommendation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.